Article
The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.
Clinical pharmacokinetics - 1 Jan 2000
Lennard M S, Tucker G T, Woods H F
Abstract excerpt
Wide variability in response to some drugs such as debrisoquine can be attributed largely to genetic polymorphism of their oxidative metabolism. Most beta-blockers undergo extensive oxidation. Anecdotal reports of high plasma concentrations of certain beta-blockers in poor metabolisers (PMs) of debrisoquine have claimed that the oxidation of these drugs is under polymorphic control. Subsequently, controlled...
Topics
- Adrenergic beta-Antagonists
- Angina Pectoris
- Asthma
- Debrisoquin
- Drug Interactions
- Ethanolamines
- Humans
- Hydroxylation
- Hypertension
- In Vitro Techniques
- Isoquinolines
- Kinetics